Society for Immunotherapy of Cancer (SITC) shared a post on LinkedIn:
“Exciting science unfolding at ESMOImmuno25!
Today’s oral abstract session featured Andreas Pircher’s presentation on, ‘Neoadjuvant induction with pembrolizumab (Pembro) plus lenvatinib (Len) in resectable early-stage NSCLC impacts the tumor microenvironment (TME): Clinical results including multi-omic deconvolution of the TME from the INNWOP01 study’.
For a deeper look, explore a recent JITC article from Jingxuan Zhang et. al of Duke University School of Medicine that examines changes in the TME and peripheral blood in patients receiving neoadjuvant pembro for NSCLC.”
More posts from ESMOImmuno25.